1.A Case of Lupus Nephritis Associated with Transiently Decreased C1 Inactivator Activity and Angioedema.
Su Jin OH ; yung Pyo KANG ; Yong Bum JANG ; Sang Woo NAM ; Myung Jae KANG ; Sik LEE ; Sung Kwang PARK ; Sung Kyew KANG ; Won KIM
Korean Journal of Nephrology 2005;24(5):828-831
C1 esterase inhibitor deficiency with consequent angioedma is an uncommon condition. Nonhereditary C1 inhibitor deficiency includes underlying disorders; lymphoproliferative disorder, autoimmune disease, hypereosinophilia, drug-induced, allergic, and idiopathic forms. The as sociation of hereditary C1 esterase inhibitor deficiency with systemic lupus erythematosus has been previously described. We experienced a case with transiently decreased C1 inactivator activity and angioedema in lupus nephritis. This present case is a previously healthy 22-year-old woman, who developed intermittent facial angioedema and decreased urine amount. After steroid treatment, the C1 inactivator activity was recovered and angioedema was disappeared.
Angioedema*
;
Angioedemas, Hereditary
;
Autoimmune Diseases
;
Female
;
Humans
;
Lupus Erythematosus, Systemic
;
Lupus Nephritis*
;
Lymphoproliferative Disorders
;
Young Adult
2.Korean multicenter clinical trial of simvastatin ( KS-1 study ).
Hyun Ho SHIN ; Kwon Bae KIM ; Jung Chaee KANG ; Min Soo SON ; Jae Hyung KIM ; Jong Seong KIM ; Seung Yun CHO ; Yung Woo SHIN ; Hyo Soo KIM ; In Ho CHAE ; Young Bae PARK ; Sung Choon CHOE ; Jung Don SEO ; Jong Hwa BAE ; Young Moo RHO ; Won Ro LEE ; Shung Chull CHAE ; Kwon Sam KIM ; Jung Chun AHN ; Cheol Ho KIM ; Jeong Euy PARK ; Cheol Whan LEE ; Jin Won JEONG ; Kyung Hoon CHOE ; Gil Ja SHIN ; Kun Joo RHEE ; Jae Ki KO ; Son Pyo HONG ; Un Ho RYOO ; Eun Seok JEON ; Dong Woon KIM ; Chong Yun RIM
Korean Journal of Medicine 1999;57(5):906-915
The aim of this study was to investigate the efficacy of simvastatin to improved lipid profiles in hypercholesterolemic Korean patients. METHODS: From 25 hospitals in Korea, 478 hypercholesterolemic patients were enrolled from November 1996 to April 1998. The inclusion criteria was hypercholesterolemia over 240 mg/dl after diet therapy for 1 month or hypercholesterolemia over 220 mg/dl in patients with definite evidence of ischemic heart disease. Simvastatin 10mg was started and doubled up to 40mg if total cholesterol level remained higher than 200 mg/dl at monthly check. Of 478 subjects, 344 patients in whom study protocol was not violated were analyzed. RESULTS: Male to female ratio was 27:73 and 47% of the subjects were in 6th decade. Hypertension, coronary artery disease, and diabetes mellitus were present in 30, 10, and 4% of the subjects. Baseline lipid profile (mean of total cholesterol-LDL-HDL-triglyceride mg/dl) was 274-185-52-188. The dose of simvastatin for 3 months was 10/10/10mg in 61% of subjects, 10/20/20mg in 21%, 10/10/20mg in 7%, and 10/20/40mg in 12%. The change of total cholesterol level(before-4wk-8wk-12wk-withdrawal 4wk) was 274-209- 205-198-250, and the maximal reduction rate was 27%. The change of LDL-cholesterol was 185-123-116-110-159, with maximal reduction rate 39%. The change of HDL-cholesterol was 52-54-56-55-54, with maximal increase rate 9%. The change of tryglyceride was 188-161- 164-162-189, with maximal reduction rate 15%. The value before/after treatment of ApoA1, ApoB, and Lp(a) was 129/129, 138/83, and 9.3/10.7, respectively. The level of LDL-cholesterol at the end of treatment was below 100mg/dl in 36% of subjects, 100-130 in 45%, 130-160 in 16%, and over 160mg/dl in 4%. The reduction rate of LDL-cholesterol was different between subjects whose LDL decreased below 100 and those whose LDL did not decrease below 130mg/dl, which suggests the existence of the individual difference of responsiveness to simvastatin. There were only 3 subjects (0.9%) who showed increase of liver enzyme over 3 times as the upper normal limit. Conclusion: Simvastatin is effective in improving lipid profiles in hypercholesterolemic Korean patients without serious side effects.
Apolipoproteins B
;
Cholesterol
;
Coronary Artery Disease
;
Diabetes Mellitus
;
Diet Therapy
;
Female
;
Humans
;
Hypercholesterolemia
;
Hypertension
;
Individuality
;
Korea
;
Liver
;
Male
;
Myocardial Ischemia
;
Simvastatin*
3.Korean multicenter clinical trial of simvastatin ( KS-1 study ).
Hyun Ho SHIN ; Kwon Bae KIM ; Jung Chaee KANG ; Min Soo SON ; Jae Hyung KIM ; Jong Seong KIM ; Seung Yun CHO ; Yung Woo SHIN ; Hyo Soo KIM ; In Ho CHAE ; Young Bae PARK ; Sung Choon CHOE ; Jung Don SEO ; Jong Hwa BAE ; Young Moo RHO ; Won Ro LEE ; Shung Chull CHAE ; Kwon Sam KIM ; Jung Chun AHN ; Cheol Ho KIM ; Jeong Euy PARK ; Cheol Whan LEE ; Jin Won JEONG ; Kyung Hoon CHOE ; Gil Ja SHIN ; Kun Joo RHEE ; Jae Ki KO ; Son Pyo HONG ; Un Ho RYOO ; Eun Seok JEON ; Dong Woon KIM ; Chong Yun RIM
Korean Journal of Medicine 1999;57(5):906-915
The aim of this study was to investigate the efficacy of simvastatin to improved lipid profiles in hypercholesterolemic Korean patients. METHODS: From 25 hospitals in Korea, 478 hypercholesterolemic patients were enrolled from November 1996 to April 1998. The inclusion criteria was hypercholesterolemia over 240 mg/dl after diet therapy for 1 month or hypercholesterolemia over 220 mg/dl in patients with definite evidence of ischemic heart disease. Simvastatin 10mg was started and doubled up to 40mg if total cholesterol level remained higher than 200 mg/dl at monthly check. Of 478 subjects, 344 patients in whom study protocol was not violated were analyzed. RESULTS: Male to female ratio was 27:73 and 47% of the subjects were in 6th decade. Hypertension, coronary artery disease, and diabetes mellitus were present in 30, 10, and 4% of the subjects. Baseline lipid profile (mean of total cholesterol-LDL-HDL-triglyceride mg/dl) was 274-185-52-188. The dose of simvastatin for 3 months was 10/10/10mg in 61% of subjects, 10/20/20mg in 21%, 10/10/20mg in 7%, and 10/20/40mg in 12%. The change of total cholesterol level(before-4wk-8wk-12wk-withdrawal 4wk) was 274-209- 205-198-250, and the maximal reduction rate was 27%. The change of LDL-cholesterol was 185-123-116-110-159, with maximal reduction rate 39%. The change of HDL-cholesterol was 52-54-56-55-54, with maximal increase rate 9%. The change of tryglyceride was 188-161- 164-162-189, with maximal reduction rate 15%. The value before/after treatment of ApoA1, ApoB, and Lp(a) was 129/129, 138/83, and 9.3/10.7, respectively. The level of LDL-cholesterol at the end of treatment was below 100mg/dl in 36% of subjects, 100-130 in 45%, 130-160 in 16%, and over 160mg/dl in 4%. The reduction rate of LDL-cholesterol was different between subjects whose LDL decreased below 100 and those whose LDL did not decrease below 130mg/dl, which suggests the existence of the individual difference of responsiveness to simvastatin. There were only 3 subjects (0.9%) who showed increase of liver enzyme over 3 times as the upper normal limit. Conclusion: Simvastatin is effective in improving lipid profiles in hypercholesterolemic Korean patients without serious side effects.
Apolipoproteins B
;
Cholesterol
;
Coronary Artery Disease
;
Diabetes Mellitus
;
Diet Therapy
;
Female
;
Humans
;
Hypercholesterolemia
;
Hypertension
;
Individuality
;
Korea
;
Liver
;
Male
;
Myocardial Ischemia
;
Simvastatin*